Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

SkyAI, Inc. (SKYA)

As of 2026-11-22 · 11/15 boxes filled from SEC filings and market data

Report price $2.18 (close 2026-11-20)

Conclusion: PASS

Conviction low · base case none · downside -40% · upside +38%

The market is pricing SKYA as a balance-sheet event, not an operating business: at $2.18 it pays 0.46x the $241.2M of shareholders' equity and 575.07x TTM revenue of $192,780, while TTM net income is -$207.3M. That makes the equity a claim on cash and book value rather than on earnings, so the call is PASS at low conviction. The downside is -40.5% to $1.30, based on -30.0% book value at a compressed P/B of 0.39x (today 0.46x). There is no base case: no independent multiple—peer median or own history—was available, and no comparable peer multiple sets one. The upside is +38.0% to $3.01, the analyst's own upside (no earnings change was given to price it). With the spread between those two cases, there is not enough to support a different call.

Key numbers

  • Share price: $2.18
  • Market cap: $110.9M
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $192,780
  • Price / book: 0.46x
  • Earnings-quality flags (TTM): Mark-to-market on the company's own stock (warrants) -$7.4M (4% of net income)

The 15 boxes

  1. ✓ 1. Long-form business notes

    SkyAI, Inc., formerly Sharps Technology Inc. until 2026-05-15, moved from a pre-commercial safety-syringe developer to a medical-device distributor plus a Solana treasury vehicle: the FY2025 10-K says it adopted a SOL treasury strategy on Aug 23, 2025 and raised ~$400M in a PIPE on Aug 28, 2025. The legacy business designed and patented safety syringes and signed Nephron distribution/manufacturing agreements in 2022, but total revenue was only $204,120 in FY2025 and $192,780 TTM to Sep 2026, with negative gross profit and operating cash flow. The SOL treasury now dominates the balance sheet and earnings: SOL is marked to fair value through net income, and a related-party consultant is paid 2.5% of the $400M digital-asset base ($10M) for the first year.

  2. ○ 2. Competitive advantage

    On GAAP figures, no durable competitive advantage is evidenced: SkyAI is an early-stage syringe seller/distributor with FY2025 revenue of $204,120, negative gross profit of $413,325, and operating income of -$269.7 million; for the TTM to 2026-09-30 revenue was $192,780, gross profit -$691,591, and operating income -$199.3 million. It competes with many medical device companies offering safety syringes, some with considerably more financial resources, and the 10-K reports net losses of $282.5 million for FY2025. The SOL-focused digital asset treasury, holding approximately 2,000,000 SOL, is a capital strategy rather than an operating moat.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 was a staking-and-treasury quarter, not an operating one: product revenue was $0 versus $68,040, net staking revenue was $2,551,013, and the $84.9 million of net income came from a $90,525,120 unrealized Solana gain (nine months to Sep 2026: net loss of $24.6 million, driven by $17,531,835 of realized crypto losses). Cash fell to $7,477,772 at September 30, 2026 from $10,382,745, with $9,145,283 used in operations and $3,112,399 spent on buybacks. After quarter-end the company sold about 2.0 million SOL for about $215 million at a roughly $163 million realized loss, leaving about $224 million of cash against a self-tender that could cost about $214.3 million if fully subscribed.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans